Free Trial

HLS Therapeutics Q1 2024 Earnings Report

HLS Therapeutics logo
C$4.65 -0.01 (-0.21%)
As of 11:33 AM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.26
Consensus EPS
-C$0.25
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$16.82 million
Expected Revenue
$19.61 million
Beat/Miss
Missed by -$2.79 million
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

HLS Therapeutics Earnings Headlines

Q1 Earnings Estimate for TSE:HLS Issued By Stifel Canada
The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
HLS Therapeutics Inc (HLS) Receives a Hold from Stifel Nicolaus
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS) Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat